SIGNAL DETECTION USING DATA FROM FDA ADVERSE EVENT REPORTING SYSTEM (FAERS): INFECTIONS IN BIOLOGICS VS BIOSIMILARS

被引：0
|
作者：
Patel, U. [1 ]
Eguale, T. [1 ]
Rittenhouse, B. [2 ]
Yunusa, I [3 ]
Kandikatla, R. [4 ]
Fathima, A. [5 ]
机构：
[1] MCPHS Univ, Boston, MA USA
[2] MCPHS Univ, Winchester, MA USA
[3] Univ South Carolina, Columbia, SC 29208 USA
[4] MCPHS Univ, Malden, MA USA
[5] MCPHS Univ, Roxbury, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EPH146
引用
收藏
页码：S191 / S191
页数：1
相关论文
共 50 条
  • [31] Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)
    Xiong, Xiaomei
    Zhang, Xiuwen
    Li, Xiaoxia
    Huang, Taomin
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (11) : 1447 - 1452
  • [32] A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
    Zou, Shu-peng
    Yang, Hai-yun
    Ouyang, Meng-ling
    Cheng, Qian
    Shi, Xuan
    Sun, Ming-hui
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [33] Metformin adverse event profile: a pharmacovigilance study based on the FDA Adverse Event Reporting System (FAERS) from 2004 to 2022
    Du, Yikuan
    Zhu, Jinfeng
    Guo, Zhuoming
    Wang, Zhenjie
    Wang, Yuni
    Hu, Mianda
    Zhang, Lingzhi
    Yang, Yurong
    Wang, Jinjin
    Huang, Yixing
    Huang, Peiying
    Chen, Mianhai
    Chen, Bo
    Yang, Chun
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (02) : 189 - 201
  • [34] Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)
    Araujo, Ariane G. S.
    Borba, Helena H. L.
    Tonin, Fernanda S.
    Lenzi, Luana
    Venson, Rafael
    Pontarolo, Roberto
    Wiens, Astrid
    BIODRUGS, 2018, 32 (04) : 377 - 390
  • [35] Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023
    Liu, Luyu
    Wu, Shaobo
    Wei, Liangliang
    Xia, Zhihao
    Ji, Jiajia
    Huang, Dageng
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2025, 37 (01)
  • [36] Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)
    Ariane G. S. Araujo
    Helena H. L. Borba
    Fernanda S. Tonin
    Luana Lenzi
    Rafael Venson
    Roberto Pontarolo
    Astrid Wiens
    BioDrugs, 2018, 32 : 377 - 390
  • [37] Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
    Chengwen Teng
    Christopher R. Frei
    Drugs - Real World Outcomes, 2022, 9 : 23 - 29
  • [38] Carfiilzomib-induced cardiotoxicity: An analysis of the FDA Adverse Event Reporting System (FAERS)
    Buck, Benjamin
    Kellett, Eric
    Addison, Daniel
    Vallakati, Ajay
    JOURNAL OF THE SAUDI HEART ASSOCIATION, 2022, 34 (03) : 134 - 141
  • [39] Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System
    Harpaz, R.
    DuMouchel, W.
    LePendu, P.
    Bauer-Mehren, A.
    Ryan, P.
    Shah, N. H.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (06) : 539 - 546
  • [40] Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
    Teng, Chengwen
    Baus, Courtney
    Wilson, James P.
    Frei, Christopher R.
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2019, 16 (11): : 1504 - 1509
12345